Stopped: End of shelf life of investigational devices.
The present study is a first-in-man, single arm, open-label, single center study to assess feasibility and safety of a novel implantable device, LymphoPilot, in patients suffering from secondary upper limb or lower lymphedema.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Occurrence, frequency and severity of device-related adverse events
Timeframe: From enrollment until final visit, 4 weeks after device removal.